Sapient

For most of my career, if you wanted to know what a tumor was doing, you sequenced it. DNA to reveal what changed, and RNA to see what's expressed. That's still how most oncology programs work today.   It's also why so many good-looking targets don't survive translation. The gene isn't the target... the protein is. And the protein doesn't always show up where the sequence says it should.   On July 23, I'm presenting a live webinar with Technology Networks on exactly this gap – and how mass spec-based proteomics now lets us measure functional tumor biology directly, at scale, in FFPE and fresh-frozen human tumors. Dimensions like target accessibility, signaling activity, and resistance biology. The things sequencing alone can't tell you.   Be sure to join me and ask your best questions during the live Q&A. 🗓 July 23 | 11:30am ET / 8:30am PT Register here: https://lnkd.in/gV8az7Zd   #Proteomics #Oncology #TumorBiology #DrugDevelopment #FFPE #MassSpectrometry

Is multi-omics reproducible? Ask a room of translational scientists and alongside real enthusiasm, you will likely find a current of skepticism. That skepticism isn't about whether an integrated view of DNA, RNA, proteins, metabolites, and lipids would elucidate human biology in ways that benefit their drug development endeavors, but about whether the field can generate integrated datasets that are rigorous enough to act on. Multi-omics workflows vary across platforms, labs, and timepoints, with no universal gold-standard pipeline. This lack of standardization leaves R&D leadership asking: what do we actually do with this data? Our new blog makes the case that the reproducibility gap is an execution problem, not a science problem, and lays out the evidence: https://lnkd.in/g86DmSe2

One week away! Click below to register to join us live, or sign up to automatically receive the on-demand recording if you can't make the time.

Find established CNS markers... and the next ones. Sapient's CSF proteomics workflow measures 𝟑,𝟔𝟎𝟎+ 𝐩𝐫𝐨𝐭𝐞𝐢𝐧 𝐠𝐫𝐨𝐮𝐩𝐬 in less than 50 µL of CSF – including both free proteins and exosomal and membrane-bound proteins released by nervous tissue. In a case-control study, established neuronal-injury markers like neurofilament light chain and tau were markedly elevated in ND patients – alongside hundreds of differentially expressed proteins, PTMs, and proteoforms that may represent novel CNS biomarkers or drug targets. ✅ ~33,800 peptides per sample, median CV 11.3% ✅ Minimum 2,498 protein groups detected per sample (n=100) ✅ 60 samples per day per instrument ✅ Cross-validate hits with NULISA™ targeted assays ▶️ Talk to our scientists: https://lnkd.in/gfXm2e9Z #CSFproteomics #CNS #neurodegeneration #biomarkers

How is tumor protein profiling complementary to – or different from – genomics? Sapient's Mo Jain, MD PhD addresses this question in the latest installment of our Q&A series delving into proteomics method innovations and their impact on oncology drug development. Dr. Jain explains that while genomics and transcriptomics reveal what a cell 𝘤𝘰𝘶𝘭𝘥 do, for most therapeutics – ADCs, T-cell engagers, kinase inhibitors – what ultimately matters is what the protein is 𝘢𝘤𝘵𝘶𝘢𝘭𝘭𝘺 doing: whether it is expressed, accessible, and present at the right level. This means pairing proteomics with genomics data produces a far more complete picture of tumor biology than either approach alone. Hear his full answer below ⬇️, and check out the other Q&A topics he's covered here:https://lnkd.in/ge2Bs64v 

Introducing the 𝐃𝐲𝐧𝐚𝐦𝐢𝐐™ 𝐍𝐨𝐫𝐦𝐚𝐥 𝐇𝐮𝐦𝐚𝐧 𝐓𝐢𝐬𝐬𝐮𝐞 𝐏𝐫𝐨𝐭𝐞𝐨𝐦𝐢𝐜𝐬 𝐀𝐭𝐥𝐚𝐬: not just a catalog of which proteins are present in normal tissues, but a comprehensive map of how they are regulated, activated, and organized across normal human biology. On-target, off-tissue toxicity a leading cause of program failure – often assessed too late and with RNA proxies instead of actual protein data. Sapient's atlas provides the baseline biological context to mitigate these liabilities earlier, looking directly at the protein level across the dimensions that actually determine therapeutic outcome, mapping across 12,000+ proteins: 🔹𝐏𝐫𝐨𝐭𝐞𝐢𝐧 𝐞𝐱𝐩𝐫𝐞𝐬𝐬𝐢𝐨𝐧 🔹𝐒𝐢𝐠𝐧𝐚𝐥𝐢𝐧𝐠 𝐚𝐜𝐭𝐢𝐯𝐢𝐭𝐲 🔹𝐒𝐮𝐫𝐟𝐚𝐜𝐞 𝐭𝐚𝐫𝐠𝐞𝐭 𝐚𝐜𝐜𝐞𝐬𝐬𝐢𝐛𝐢𝐥𝐢𝐭𝐲 🔹𝐈𝐦𝐦𝐮𝐧𝐞 𝐛𝐢𝐨𝐥𝐨𝐠𝐲 🔹𝐑𝐞𝐬𝐢𝐬𝐭𝐚𝐧𝐜𝐞 𝐩𝐚𝐭𝐡𝐰𝐚𝐲𝐬 With this data, you can prioritize tumor-selective target candidates with favorable therapeutic index profiles, assess baseline organ-level vulnerabilities, and predict potential immune-related adverse events – supporting more confident target selection and safety decisions. https://lnkd.in/g_VKmUdS

Targeted protein degraders are opening up targets long considered undruggable… the challenge with this modality is ensuring 𝐬𝐞𝐥𝐞𝐜𝐭𝐢𝐯𝐢𝐭𝐲. The drug must remove its intended target without degrading other proteins, even as the tumor adapts. Most degrader assays track only one or a few proteins at a time, making it easy to miss off-target degradation. Our mass spectrometry-based Protein Degrader Proteomics solves that, measuring thousands of proteins at once – without antibodies and without choosing targets in advance. See how this single platform can be applied from the first screen through the clinic, ensuring directly comparable results: https://lnkd.in/g6vUiep5

'Seek' to find actionable drug targets and functional tumor biology. An early biomarker of HIE severity discovered. Multi-omics exosome profiling distinguishes regenerative & inflammatory vesicle populations. FFPE proteomics draws a crowd at #ASMS2026. Find 𝐓𝐡𝐞 𝐈𝐍𝐬𝐢𝐠𝐡𝐭 you need to stay up-to-date with these multi-omics advances and more in our latest quarterly #newsletter: https://lnkd.in/gxWbri6j You can also subscribe to automatically receive upcoming issues: https://lnkd.in/gPxF-3G2 #INsight #discovermore

Robust cytokine measures, 𝐝𝐢𝐟𝐟𝐞𝐫𝐞𝐧𝐭𝐢𝐚𝐭𝐞𝐝 𝐢𝐧𝐬𝐢𝐠𝐡𝐭𝐬. As an Alamar Biosciences, Inc. Certified Service Provider for #NULISA panels and the only multi-omics partner with a molecular-clinical database in which to confirm findings from these assays, Sapient uniquely offers: ✅ The full range of NULISA panels and assays, from NULISAseq Inflammation, CNS Disease, and Mouse Panels to NULISAqpcr assays for absolute quantitation of key biomarkers like BD-pTau217 ✅ Complementary omics approaches to orthogonally validate NULISA data or integrate additional molecular data layers ✅ Integrative statistical and ML analysis of NULISA data with additional phenotypic and/or omics data ✅ Biological contextualization of identified markers using our DynamiQ™ Insights Engine Tap our deep expertise in NULISA technologies and assay development to obtain robust measures for difficult-to-assay cytokines, chemokines, and inflammatory mediators. Request a study today: https://lnkd.in/gMfsgGVt

Oncology programs often rely on DNA and RNA data to guide decisions – but genomics can only 𝘱𝘳𝘦𝘥𝘪𝘤𝘵 target accessibility, pathway activity, and resistance. Protein-level measurements provide 𝐝𝐢𝐫𝐞𝐜𝐭 𝐞𝐯𝐢𝐝𝐞𝐧𝐜𝐞 of this dynamic functional tumor biology. Join our #webinar to: — Explore advancements that have made the functional proteome accessible at scale in human tumors, across the dimensions that determine whether a drug will be effective in the patient tumor. — See real-world examples of how these protein-level insights have revealed novel druggable targets, enabled deep characterization of immune and signaling activity, and uncovered resistance-associated biology that may be missed by sequencing alone. 📅 Thursday, July 23 at 11:30am ET / 8:30am PT Hosted by Technology Networks Presented by Sapient's Mo Jain, MD PhD Register today: https://lnkd.in/gxDh6fEx